Treatment-induced amplification of the therapeutic target, i.e., AR, is not the only problem, as treatment-naïve PCa is already heterogeneous with respect to AR expression such that there exist a population of AR non-expressing (AR−/lo) PCa cells [15,39–42]. This evidence concerns the gene AR and posterior cortical atrophy.